Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
$0.03
-6.9%
$0.04
$0.00
$0.78
$1.49M1.187,440 shs284 shs
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
$0.32
-12.1%
$0.48
$0.32
$3.10
$5.20M1.49146,449 shs191,558 shs
TransCode Therapeutics, Inc. stock logo
RNAZ
TransCode Therapeutics
$6.87
-1.4%
$11.40
$6.15
$1,838.76
$5.72M1.52100,542 shs41,015 shs
Soligenix, Inc. stock logo
SNGX
Soligenix
$1.91
+5.5%
$2.01
$1.68
$14.83
$6.23M2.06763,600 shs17,105 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
0.00%-6.93%-68.27%+15.95%-86.04%
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
-12.11%-17.94%-31.15%-60.33%-86.14%
TransCode Therapeutics, Inc. stock logo
RNAZ
TransCode Therapeutics
-1.43%-2.00%-35.43%-92.68%-99.99%
Soligenix, Inc. stock logo
SNGX
Soligenix
+5.52%-3.05%-11.98%-16.23%-67.29%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
3.0116 of 5 stars
3.55.00.00.01.11.71.3
TransCode Therapeutics, Inc. stock logo
RNAZ
TransCode Therapeutics
2.5455 of 5 stars
3.52.00.00.04.10.01.3
Soligenix, Inc. stock logo
SNGX
Soligenix
1.0036 of 5 stars
0.05.00.00.01.50.01.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
0.00
N/AN/AN/A
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
3.00
Buy$8.502,521.03% Upside
TransCode Therapeutics, Inc. stock logo
RNAZ
TransCode Therapeutics
3.00
Buy$280.003,975.69% Upside
Soligenix, Inc. stock logo
SNGX
Soligenix
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ADXS, INDP, SNGX, and RNAZ Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/16/2025
TransCode Therapeutics, Inc. stock logo
RNAZ
TransCode Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$560.00 ➝ $280.00
3/13/2025
TransCode Therapeutics, Inc. stock logo
RNAZ
TransCode Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$560.00 ➝ $560.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
$3.24M0.46N/AN/A($2.06) per share-0.02
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
N/AN/AN/AN/A$1.44 per shareN/A
TransCode Therapeutics, Inc. stock logo
RNAZ
TransCode Therapeutics
N/AN/AN/AN/A$86.32 per shareN/A
Soligenix, Inc. stock logo
SNGX
Soligenix
-$117.03K-53.27N/AN/A$3.83 per share0.50
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
-$48.07M-$7.98N/AN/AN/AN/AN/AN/A
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
-$15.42M-$1.49N/AN/AN/AN/A-177.27%-141.06%8/11/2025 (Estimated)
TransCode Therapeutics, Inc. stock logo
RNAZ
TransCode Therapeutics
-$18.55MN/A0.00N/AN/AN/A-649.03%-281.34%N/A
Soligenix, Inc. stock logo
SNGX
Soligenix
-$6.14M-$4.29N/AN/AN/A-1,473.38%-223.29%-74.18%8/8/2025 (Estimated)

Latest ADXS, INDP, SNGX, and RNAZ Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/21/2025Q4 2024
TransCode Therapeutics, Inc. stock logo
RNAZ
TransCode Therapeutics
-$2.00-$0.60+$1.40-$2.51$0.30 millionN/A
5/14/2025Q1 2025
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
-$0.41-$0.32+$0.09-$0.32N/AN/A
5/9/2025Q1 2025
Soligenix, Inc. stock logo
SNGX
Soligenix
-$0.67-$1.06-$0.39-$1.06N/AN/A
3/21/2025Q4 2024
Soligenix, Inc. stock logo
SNGX
Soligenix
-$0.95-$1.14-$0.19-$1.14$0.20 million$0.20 million
3/13/2025Q4 2024
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
-$0.41-$0.38+$0.03-$0.38N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
N/AN/AN/AN/AN/A
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
N/AN/AN/AN/AN/A
TransCode Therapeutics, Inc. stock logo
RNAZ
TransCode Therapeutics
N/AN/AN/AN/AN/A
Soligenix, Inc. stock logo
SNGX
Soligenix
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
N/AN/AN/A
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
N/A
3.42
3.42
TransCode Therapeutics, Inc. stock logo
RNAZ
TransCode Therapeutics
N/A
1.58
1.58
Soligenix, Inc. stock logo
SNGX
Soligenix
N/A
2.28
2.28

Institutional Ownership

CompanyInstitutional Ownership
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
7.18%
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
7.06%
TransCode Therapeutics, Inc. stock logo
RNAZ
TransCode Therapeutics
N/A
Soligenix, Inc. stock logo
SNGX
Soligenix
3.60%

Insider Ownership

CompanyInsider Ownership
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
0.63%
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
29.50%
TransCode Therapeutics, Inc. stock logo
RNAZ
TransCode Therapeutics
0.10%
Soligenix, Inc. stock logo
SNGX
Soligenix
3.05%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
2042.63 million42.36 millionNot Optionable
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
616.03 million9.96 millionNot Optionable
TransCode Therapeutics, Inc. stock logo
RNAZ
TransCode Therapeutics
9833,000677,000Not Optionable
Soligenix, Inc. stock logo
SNGX
Soligenix
203.26 million2.44 millionNot Optionable

Recent News About These Companies

Soligenix selects IBN to spearhead corporate communications
IBN Initiates Coverage of Soligenix Inc.

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ayala Pharmaceuticals stock logo

Ayala Pharmaceuticals NASDAQ:ADXS

$0.03 0.00 (-6.93%)
As of 05/23/2025

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.

Indaptus Therapeutics stock logo

Indaptus Therapeutics NASDAQ:INDP

$0.32 -0.04 (-12.11%)
Closing price 05/27/2025 03:58 PM Eastern
Extended Trading
$0.34 +0.02 (+6.07%)
As of 05/27/2025 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

TransCode Therapeutics stock logo

TransCode Therapeutics NASDAQ:RNAZ

$6.87 -0.10 (-1.43%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$6.95 +0.08 (+1.18%)
As of 05/27/2025 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.

Soligenix stock logo

Soligenix NASDAQ:SNGX

$1.91 +0.10 (+5.52%)
Closing price 05/27/2025 03:59 PM Eastern
Extended Trading
$1.91 0.00 (0.00%)
As of 05/27/2025 06:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.